… 28, 2014 - RaceTrac announced that its cumulative giving to The Michael J. Fox Foundation for Parkinson's Research … executed various initiatives over the years encouraging the community to participate in and support a worthy cause. "In four short years, RaceTrac has shown incredible generosity and commitment not only …

… Projects aim to genetically test samples from more than 30,000 people by … and progression can help researchers develop and test targeted treatments Program builds on Foundation’s longstanding support of genetic research and commitment to diversity and inclusivity in clinical research …

… Therapeutics LLC) is a small molecule and a selective inhibitor of a neuroinflammatory pathway known as NLRP3. Taken … Initial studies in preclinical mouse models show that dapansutrile reduces the levels of alpha-synuclein … could start as soon as practical following successful completion of the proposed preclinical studies. …

… No matter where the starting line is located, our community continues to go the distance to bring us closer to our ultimate finish … a role in bringing the worldwide Parkinson’s community together through on-ramps of virtual activities with a shared …

… is the gold standard treatment for Parkinson’s disease. However, its continued use results in serious side effects … a new class of drugs, type 7 phosphodiesterase (PDE7) inhibitors, restore normal movements in pre-clinical models of … Description: We will first test a number of PDE7 inhibitor compounds for potency, safety, ability to enter the brain, …

… of Parkinson’s disease, no direct dopamine agonist compares in efficacy to levodopa, suggesting that levodopa itself or its metabolites may affect targets in addition to dopamine receptors to fully manifest its … Symptoms & Side Effects … Target Validation …